{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-22-000010","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.161282+00:00","generated_at":"2026-06-21T22:30:00.505488+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune Q3 net loss $23.5M, cash $201.9M; pemvidutide NAFLD data mid-Dec, obesity interim Q1 2023","bullets":["Net loss of $23.5M ($0.48 per share) vs $33.5M loss YoY; revenue minimal at ~$0.","Cash, equivalents & short-term investments totaled $201.9M at September 30, 2022.","Topline 24-week data from Phase 1b NAFLD trial expected mid-December 2022.","Interim 24-week readout from Phase 2 MOMENTUM obesity trial (~160 subjects) expected Q1 2023.","Enrollment complete in Phase 1b type 2 diabetes trial; data readout expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-22-000010","json":"https://secwatch.observer/filing/0001326190-22-000010.json","markdown":"https://secwatch.observer/filing/0001326190-22-000010.md","text":"https://secwatch.observer/filing/0001326190-22-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/0001326190-22-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/alt-20221110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:30:00.505488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51b2eed5a6c689bfbfe26a8c053473640d347b0e","claim":"Altimmune, Inc. reported financial results for three months ended September 30, 2022.","evidence_excerpt":"Revenue was minimal for the three months ended September 30, 2022 compared to $0.2 million in the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/0001326190-22-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}